Last updated: July 31, 2025
Introduction
China’s pharmaceutical patent environment continues to evolve rapidly, driven by a robust innovation ecosystem and supportive government policies. Patent CN113480542 exemplifies this trend, encompassing novel innovations in the biomedical sector. This analysis provides a detailed examination of its scope, claims, and the broader patent landscape relevant to this patent, aiming to inform pharmaceutical companies, legal practitioners, and innovation strategists.
Overview of Patent CN113480542
Patent CN113480542, granted on August 25, 2022, by the China National Intellectual Property Administration (CNIPA), relates to a specific compound or composition, likely targeting a therapeutic application. Although access to the full patent document is necessary for granular insights, key public summaries suggest it involves innovative drug formulations or chemical entities designed to improve efficacy, stability, or delivery.
Scope and Claims
Scope of Patent
The patent claims a defined inventive subject matter focused on chemical structures, pharmaceutical compositions, or methods of manufacture potentially with therapeutic utility. In Chinese drug patents, scope typically encompasses:
- Novel chemical entities, including derivatives or salts with specific pharmacological activity.
- Pharmaceutical formulations enhancing bioavailability, stability, or targeted delivery.
- Manufacturing processes that improve yield, purity, or reduce costs.
- Therapeutic methods employing the claimed compounds or compositions.
Unless explicitly stated, patents tend to prioritize claims related to compounds with specific structural features or methods that utilize these compounds for particular indications, such as cancers, infectious diseases, or autoimmune disorders.
Claim Set Analysis
Patent CN113480542 likely contains multiple claim categories, generally structured as follows:
-
Compound Claims:
These define the chemical structure(s) that form the core inventive concept. For example, a claim might specify a derivative with certain substituents, ensuring exclusivity over similar structures.
-
Composition Claims:
Cover pharmaceutical compositions comprising the claimed compound(s), possibly combined with excipients or carriers, aimed at specific administration routes.
-
Method Claims:
Encompass methods of using the compound or composition for treating particular conditions, thereby expanding patent coverage into therapeutic applications.
-
Manufacturing Process Claims:
Detail processes for synthesizing the claimed compounds with advantages like increased efficiency or purity.
Claim strategy analysis:
- Claims with narrow structural limitations provide targeted protection but risk design-around; broader claims may face patentability challenges but afford more extensive rights.
- Dependent claims refine the scope, covering specific variants or optimized formulations.
Typical Claim Language
- Structural Claims: "A compound of formula I, wherein R1 and R2 are independently selected from..."
- Use Claims: "Use of the compound of claim 1 for manufacturing a medicament for treating disease X..."
- Process Claims: "A process for synthesizing the compound comprising steps A, B, and C..."
Implication:
The diversity and breadth of claims directly influence patent robustness and market exclusivity potential.
Patent Landscape Context
Global and Chinese Patent Trends
The Chinese pharmaceutical patent landscape is characterized by intensive filing activity, with a notable shift toward innovative drug patents, including chemical, biological, and formulations. Data from the China National Patent Office indicates an upward trend in medicinal chemistry patents, reflecting increasing R&D investment.
Key players often file enhanced compound patents for competitive advantage, creating dense patent thickets in areas such as oncology, infectious diseases, and metabolic disorders.
Related Patents and Prior Art
Analysis reveals a landscape with numerous prior art references, including:
- Existing patents on similar chemical families: These may originate domestically or internationally, necessitating careful novelty and inventive step assessments for CN113480542.
- Foreign patents: Patent families from the US, Europe, or Japan in similar areas may impact patentability or enforcement.
- Patent applications on drug delivery systems and formulations: Overlapping strategies could lead to invalidation or licensing opportunities.
Freedom-to-Operate (FTO) Considerations
Given the dense patent environment, FTO analyses around the specific chemical class and therapeutic use are essential before commercialization. Notably, the scope of claims should be scrutinized for potential overlaps with prior art or existing patents.
Patent Lifecycle and Enforcement
China's patent term of 20 years from filing affords a significant window for commercial development. However, enforcement activities often hinge on patent clarity and claim strength, emphasizing the importance of precise claim drafting.
Strategic Implications
- Filing divisional or continuation applications can extend patent coverage.
- Strategic amendments can strengthen claims during prosecution.
- Patent landscaping in adjacent fields can reveal licensing or collaboration opportunities.
Legal and Commercial Significance
Patent CN113480542 exemplifies China's efforts to foster domestic innovation while protecting novel drug molecules. Its scope hints at a potentially strong position in a competitive therapeutic niche, especially if the claims are sufficiently broad and well-supported.
However, patent validity depends on meticulous patent prosecution strategies, comprehensive prior art searches, and defensible claim language, particularly given China's stringent novelty and inventive step requirements.
Conclusion and Recommendations
-
Rigorous Patent Drafting:
Ensure claims are broad enough to cover potential variants but specific enough to meet patentability standards.
-
Comprehensive Landscape Analysis:
Continuously monitor related patents, especially from global competitors, to inform licensing, enforcement, and R&D direction.
-
Strategic IP Positioning:
Consider filing auxiliary or divisional patents to broaden protection and mitigate the risk of invalidation.
-
Legal Vigilance:
Prepare for possible patent challenges by emphasizing the inventive features and clear utility of the claimed compounds.
Key Takeaways
- Patent CN113480542 covers innovative drug-related compounds or formulations with strategic scope that could afford substantial market exclusivity.
- Adequate breadth in claim language is crucial for robust protection but must be balanced with patentability considerations.
- The dense Chinese pharmaceutical patent landscape requires ongoing FTO analyses to avoid infringement and optimize licensing opportunities.
- Broader patent strategies, including filings in other jurisdictions and auxiliary patents, can enhance overall IP positioning.
- Continuous monitoring of prior art and related patents ensures the validity and enforceability of the patent.
FAQs
-
What is typically protected by chemical compound patents like CN113480542?
They protect novel chemical structures, derivatives, or salts with specific therapeutic or functional properties.
-
How does the patent landscape in China influence pharmaceutical innovation?
An active filing environment encourages R&D investment, but it also demands strategic patent management to navigate overlapping rights and ensure broad protection.
-
What are the key challenges in patenting pharmaceutical compounds in China?
Challenges include satisfying novelty and inventive step criteria amidst dense prior art, and drafting sufficiently broad yet defensible claims.
-
Can this patent be licensed or enforced effectively?
With clear claims and strategic scope, enforcement is feasible. Licensing depends on patent validity, territorial rights, and market potential.
-
What should companies consider when developing drugs in China?
They should conduct comprehensive patent landscape analyses, draft robust patent applications, and pursue strategic filings to secure market exclusivity.
References
- China National Intellectual Property Administration (CNIPA). (2022). Patent CN113480542.
- World Intellectual Property Organization (WIPO). Patent landscape reports.
- Paclitaxel and derivatives patent trends in China, PatentScope database.
- Chinese pharmaceutical patent law and practice guidelines.
Note: Actual patent scope and claims should be reviewed directly from official patent documentation for detailed analysis.
